Summary

Market Size & Trends

The U.S. pediatric diabetes management market size was estimated at USD 2,015.9 million in 2024 and is projected to reach USD 4,691.2 million in 2033, registering a CAGR of 9.9% from 2025 to 2033. The market growth is driven by several factors, including the rising prevalence of diabetes among children and adolescents, technological advancements in diabetes management devices, and the growing awareness of early diagnosis and the importance of proactive diabetes management. Additionally, government support and advantageous regulatory policies, such as efforts to enhance access to care, further drive market growth.

The U.S. is witnessing a significant rise in diabetes prevalence among children, necessitating a rise in demand for diabetes management solutions. Furthermore, the shift towards proactive and preventative healthcare, coupled with increased awareness among parents and healthcare providers, has fueled early diagnosis and intervention, further expanding the market. The market's expansion is also influenced by the availability of advanced healthcare infrastructure, including specialized pediatric clinics and hospitals equipped to handle complex diabetes cases. The growing emphasis on patient education and support programs, facilitated by both government and private organizations, contributes to improved disease management. For instance, the Project Power for Youth by the American Diabetes Association (ADA), a free, community- and school-based program, is designed to help children aged 5 to 12 reduce their risk of type 2 diabetes and manage obesity-related behaviors. The program educates youth on the importance of healthy eating and regular physical activity through interactive, age-appropriate content.

Moreover, technological innovation plays a crucial role in driving the growth of the pediatric diabetes management market. The development of advanced insulin pumps, CGM systems, and integrated diabetes management platforms has significantly improved pediatric diabetes management. Moreover, several market players are focusing on developing advanced solutions that can automate insulin delivery, which can further drive the adoption of these devices. For instance, in March 2025, Tandem Diabetes Care launched Control-IQ+ automated insulin delivery technology in the U.S., extending its use to people with type 1 diabetes aged 2 years and older, and adults with type 2 diabetes. Compatible with the t:slim X2 insulin pump and Tandem Mobi System, Control-IQ+ features expanded weight and insulin parameters, enhanced extended bolus up to 8 hours, and new temporary basal rate adjustments to better manage glucose during exercise, stress, or illness. It includes AutoBolus for automatic correction doses and aims to improve glucose control, ease of use, and personalization for diverse users. The continuous evolution of these technologies, coupled with their increasing affordability and ease of use, is further expected to drive market expansion.

U.S. Pediatric Diabetes Management Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pediatric diabetes management market report based on product, technology, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Blood Glucose Monitors (BGM)
• Continuous Glucose Monitors (CGM)
• Insulin Pumps
• Insulin Pens
• Insulin Syringes
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Connected Devices
• Non-connected Devices
• End Use Channels Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
o General Hospitals
o Children Hospitals
• Homecare
• Pediatric Clinics

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Technology Segment
1.2.3. End use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. U.S. Pediatric Diabetes Management Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of diabetes in children
3.2.1.2. Technological advancements
3.2.1.3. Rising awareness about diabetes management
3.2.2. Market restraint analysis
3.2.2.1. High cost of diabetes management devices
3.3. U.S. Pediatric Diabetes Management Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
Chapter 4. U.S. Pediatric Diabetes Management Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Pediatric Diabetes Management Market Product Movement Analysis
4.3. U.S. Pediatric Diabetes Management Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Blood Glucose Monitors (BGM)
4.4.1. Blood Glucose Monitors (BGM) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Continuous Glucose Monitors (CGM)
4.5.1. Continuous Glucose Monitors (CGM) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Insulin Pumps
4.6.1. Insulin pumps market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.7. Insulin Pens
4.7.1. Insulin pens market revenue estimates and forecasts, 2021 - 2033 (USD Million)
4.8. Insulin Syringes
4.8.1. Insulin syringes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Pediatric Diabetes Management Market: Technology Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Pediatric Diabetes Management Market Technology Movement Analysis
5.3. U.S. Pediatric Diabetes Management Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
5.4. Connected Devices
5.4.1. Connected devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Non-connected Devices
5.5.1. Non-connected devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Pediatric Diabetes Management Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Pediatric Diabetes Management Market End Use Movement Analysis
6.3. U.S. Pediatric Diabetes Management Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Hospitals
6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.4.2. General Hospitals
6.4.2.1. General hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.4.3. Children Hospitals
6.4.3.1. Children hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Homecare
6.5.1. Homecare market revenue estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Pediatric Clinics
6.6.1. Pediatric clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. Medtronic
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Dexcom
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Abbott
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Tandem Diabetes Care
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Insulet Corporation
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Novo Nordisk
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Sanofi
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Eli Lilly and Company
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Roche Diabetes Care
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Ascensia Diabetes Care
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives